Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
22 hedge funds and large institutions have $2.26M invested in Sonnet BioTherapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
38% more funds holding
Funds holding: 16 → 22 (+6)
37% more capital invested
Capital invested by funds: $1.65M → $2.26M (+$613K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$503K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$140K |
| 3 |
Millennium Management
New York
|
+$134K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$70.2K |
| 5 |
CAM
Campion Asset Management
Falls Church,
Virginia
|
+$31.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$158K |
| 2 |
VF
Virtu Financial
New York
|
-$49.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$32.1K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$19K |
| 5 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
-$7K |
SONN Hedge Fund Activity: Q1 2022 in Review
22 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q1 2022, worth a combined $2.26M — up 37% from $1.65M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SONN positions and 2 closed out — a net gain of 6 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $503K. The largest seller was Geode Capital Management, cutting an estimated $158K.
- 22 institutional investors held Sonnet BioTherapeutics (SONN) as of Q1 2022, up from 16 in Q4 2021.
- Funds reported $2.26M of Sonnet BioTherapeutics stock for Q1 2022, up 37% quarter-over-quarter.
- 8 funds opened new Sonnet BioTherapeutics positions in Q1 2022 and 2 closed out, a net change of +6 holders.
- The largest Sonnet BioTherapeutics buyer in Q1 2022 was Renaissance Technologies, an estimated $503K added.
- The largest Sonnet BioTherapeutics seller in Q1 2022 was Geode Capital Management, an estimated $158K sold.
Based on aggregated 13F filings for Q1 2022.